Cure My Disease

Don't miss your cure!

 Log in / Sign up

Huntington disease gene study seeks 600 volunteers

NCT ID NCT06667414

Knowledge-focused Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 4 times

Summary

This study enrolls 600 adults with Huntington disease to examine specific genetic markers (SNPs) linked to the disease. Participants provide a blood sample and answer questions about their health and medications. The goal is to better understand the genetics of Huntington disease, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify genetic markers that may guide future treatments for Huntington disease.
What could go wrong
This is an observational study, not a treatment trial. It will not directly benefit participants and may not lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

574 people

The number who actually took part.

Started

Sep 2024

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This epidemiological study will be conducted in ambulatory men and women aged 25 to 60 years old (inclusive) who carry the Huntington Disease (HD) gene expansion and meet the Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score (TMS) and Total Functional Capacity (TFC) criteria for HD Integrated Staging System (HD-ISS) Stages 2-3.

Ages

25 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have signed the Informed Consent Form (ICF) * Aged 25 to 60 years, inclusive, at the time of signing the ICF * Confirmation of Huntington Disease (HD) gene expansion mutation carrier status * Confirmation of Total Functional Capacity (TFC) ≥9 and Total Motor Score (TMS) \>6 within 12 months prior to signing the ICF * Ability to tolerate blood draws Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Huntington disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Huntington disease

Contacts and locations

Locations

  • Addenbrookes Hospital

    Cambridge, CB2 0QQ, United Kingdom

  • Auckland DHB - Neurlogy Department

    Auckland, New Zealand

  • Barrow Neurological Institute

    Phoenix, Arizona, 85013, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Birmingham and Solihull Mental Health Foundation NHS Trust

    Birmingham, B16 8PF, United Kingdom

  • CNS - Campus Neurológico

    Torres Vedras, 2560-280, Portugal

  • Calvary Health Care Bethlehem

    Caulfield South, New South Wales, 3162, Australia

  • CenExel Rocky Mountain Clinical Research, LLC

    Englewood, Colorado, 80113, United States

  • Centricity Research

    Halifax, Nova Scotia, B3S 1N2, Canada

  • Charité - Universitätsmed. Berlin, Klinik für Psychiatrie und Psychotherapie

    Berlin, 10117, Germany

  • EvergreenHealth Investigational Drug Services

    Kirkland, Washington, 98034, United States

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Lombardy, 20133, Italy

  • Graylands Hospital

    Mount Claremont, Western Australia, 6010, Australia

  • Hospital Britanico de Buenos Aires

    Ciudad Autonoma Buenos Aires, C1284AEB, Argentina

  • Hospital Ramon y Cajal

    Madrid, 28034, Spain

  • Hospital Universitario de Badajoz

    Badajoz, 06080, Spain

  • Hospital Universitario de Burgos. Servicio de Neurología

    Burgos, 09006, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08041, Spain

  • John Hopkins University School of Medicine

    Baltimore, Maryland, 21287, United States

  • John Radcliffe Hospital

    Oxford, OX3 9DU, United Kingdom

  • McGill University

    Montreal, Quebec, H3A 2B4, Canada

  • National Hospital For Neurology and Neurosurgery

    London, WC1N 3BG, United Kingdom

  • New Zealand Brain Research Institute

    Christchurch, 8011, New Zealand

  • North York General Hospital

    Toronto, Ontario, M2J 1V1, Canada

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Rigshospitalet, Hukommelsesklinikken

    København Ø, 2100, Denmark

  • Royal Melbourne Hospital

    Parkville, Victoria, 3050, Australia

  • St. Josef-Hospital, Neurologische Klinik der Ruhr-Uni

    Bochum, 44791, Germany

  • Szpital Sw. Wojciecha

    Gda?sk, 80-462, Poland

  • Uab Medicine

    Birmingham, Alabama, 35294, United States

  • Unidade Local de Saude de Santa Maria, E.P.E. - Hospital de Santa Maria

    Lisbon, 1649-035, Portugal

  • Universita Degli Studi Di Firenze

    Florence, Tuscany, 50134, Italy

  • University of Alberta

    Edmonton, Alberta, T6G 2G3, Canada

  • University of British Columbia Hospital

    Vancouver, British Columbia, V6T 2B5, Canada

  • University of California Davis Medical System

    Sacramento, California, 95817, United States

  • University of California San Diego

    La Jolla, California, 92037-1337, United States

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa, 52242, United States

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15213, United States

  • University of South Florida

    Tampa, Florida, 33612, United States

  • Universitätsklinikum Erlangen, Abteilung Molekulare Neurologie

    Erlangen, 91054, Germany

  • Universitätsklinikum Ulm

    Ulm, 89081, Germany

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37212, United States

  • Wellington Hospital

    Wellington, 6021, New Zealand

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia

  • Wojskowy Instytut Medycyny Lotniczej

    Warsaw, 01-755, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.